Castle Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences, Inc. (NASDAQ: CSTL) will present company overviews at multiple investor conferences this November. These include the Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. ET, the Stephens Annual Investment Conference on Nov. 16, 2022, at 11:00 a.m. ET, and the Canaccord Genuity MedTech Conference on Nov. 17, 2022, at 11:30 a.m. ET. Live webcasts will be accessible on their website, with replays available post-event.

Castle focuses on diagnostics, offering tests for skin cancers and other diseases.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month:

• Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. Eastern time.
• Stephens Annual Investment Conference on Nov. 16, 2022, at 11:00 a.m. Eastern time.
• Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum on Nov. 17, 2022, at 11:30 a.m. Eastern time.

Live audio webcasts of the Company’s presentations will be available on Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005141/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com



Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

What are the dates for Castle Biosciences' upcoming investor presentations?

Castle Biosciences will present at the following events: Credit Suisse on Nov. 9, 2022, Stephens Annual Investment Conference on Nov. 16, 2022, and Canaccord Genuity Conference on Nov. 17, 2022.

What time will Castle Biosciences present at the Credit Suisse conference?

Castle Biosciences is scheduled to present at the Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. ET.

Where can I access the webcasts of Castle Biosciences' presentations?

Live audio webcasts of Castle Biosciences' presentations will be available on their website, with replays accessible afterward.

What is Castle Biosciences' focus in the diagnostics market?

Castle Biosciences specializes in innovative diagnostic tests that guide patient care, including tests for skin cancers and mental health.

Who can be contacted for investor relations at Castle Biosciences?

Camilla Zuckero handles investor relations at Castle Biosciences, reachable via email at czuckero@castlebiosciences.com.